Tao of stenting – J&J’s yin
This article was originally published in The Gray Sheet
First full quarter of drug-eluting stent sales in U.S. generates $429 mil. in revenue, accounting for 45% of all U.S. stent procedures and 90% of Johnson & Johnson's overall Q3 stent sales. Internationally, Cypher produced roughly $60 mil. in revenue. General medical devices and diagnostic sales increased 20%, to $3.78 bil., outshining pharmaceuticals, which only saw a 13% gain, to $4.84 bil...
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.